Prediction Case File
YouTubeEvaluation Complete

Novo Nordisk is losing market share in the lucrative weight loss treatment category.

1 extracted signal · 1 resolved · 0 still active

Parkev Tatevosian, CFA profile imageParkev Tatevosian, CFAIndependent analyst profile
Source published
19 Nov 2025, 20:45 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Novo Nordisk is losing market share in the lucrative weight loss treatment category.
Source overview

AI-generated source summary

Novo Nordisk is currently navigating a challenging GLP-1 market due to competition from compounders and Eli Lilly, whose treatments are showing superior performance. This has led to a significant decline in Novo Nordisk's stock, currently trading at $48.46, close to its 52-week low of $45.00. Despite these market headwinds, the company's obesity care segment reported a 41% sales increase in the most recent quarter, with US operations growing 24% and international operations 83%. Wegovy sales alone reached approximately DKK 20 billion, representing a 168% year-over-year growth. Novo Nordisk maintains a dominant 68% market share in the combined diabetes and obesity GLP-1 international market, with Ozempic launched in around 80 countries. While weekly Ozempic prescriptions in the US saw a 20,000 unit decrease from Q2 to Q3 2025, the overall GLP-1 diabetes market grew 10% in Q3 2025 compared to Q3 2024. The company is investing in commercial activities, including direct-to-patient offerings and collaborations with GoodRx and Costco, and is working with the US administration for broader treatment accessibility. A key future catalyst is the anticipated regulatory decision for the oral Wegovy pill later this year, with a planned launch in early 2026. This would make Novo Nordisk the first to market with an oral obesity treatment. The analyst's fair value calculation for Novo Nordisk is $67.73, suggesting a buying opportunity for long-term investors despite the current bearish market trend, with a calculated failure bound at $40.00.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
1
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
1
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
1 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

Parkev Tatevosian, CFA

Platform-wide history, separate from this source evaluation.

Reliability
41.8
Tracked signals
1293
Historical success
25.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail